Literature DB >> 24636248

Effect of lacosamide on structural damage and functional recovery after traumatic brain injury in rats.

A Pitkänen1, R Immonen2, X Ndode-Ekane2, O Gröhn2, T Stöhr3, J Nissinen2.   

Abstract

In a subgroup of patients, traumatic brain injury (TBI) results in the occurrence of acute epileptic seizures or even status epilepticus, which are treated with antiepileptic drugs (AEDs). Recent experimental data, however, suggest that administration of AEDs at the early post-injury phase can compromise the recovery process. The present study was designed to assess the profile of a novel anticonvulsant, lacosamide (Vimpat) on post-TBI structural, motor and cognitive outcomes. Moderate TBI was induced by lateral fluid-percussion injury in adult rats. Treatment with 0.9% saline or lacosamide (30 mg/kg, i.p.) was started at 30 min post-injury and continued at 8h intervals for 3d (total daily dose 90 mg/kg/d). Rats were randomly assigned to 4 treatment groups: sham-operated controls treated with vehicle (Sham-Veh) or lacosamide (Sham-LCM) and injured animals treated with vehicle (TBI-Veh) or lacosamide (TBI-LCM). As functional outcomes we tested motor recovery with composite neuroscore and beam-walking at 2, 7, and 15 d post-injury. Cognitive recovery was tested with the Morris water-maze at 12-14 d post-TBI. To assess the structural outcome, animals underwent magnetic resonance imaging (MRI) at 2 d post-TBI. At 16d post-TBI, rats were perfused for histology to analyze cortical and hippocampal neurodegeneration and axonal damage. Our data show that at 2 d post-TBI, both the TBI-Veh and TBI-LCM groups were equally impaired in neuroscore. Thereafter, motor recovery occurred similarly during the first week. At 2 wk post-TBI, recovery of the TBI-LCM group lagged behind that in the TBI-VEH group (p<0.05). Performance in beam-walking did not differ between the TBI-Veh and TBI-LCM groups. Both TBI groups were similarly impaired in the Morris water-maze at 2 wk post-TBI. MRI and histology did not reveal any differences in the cortical or hippocampal damage between the TBI-Veh and TBI-LCM groups. Taken together, acute treatment with LCM had no protective effects on post-TBI structural or functional impairment. Composite neuroscore in the TBI-LCM group lagged behind that in the TBI-Veh group at 15 d post-injury, but no compromise was found in other indices of post-TBI recovery in the LCM treated animals.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiepileptic drug; Lateral fluid-percussion; Magnetic resonance imaging; Neurodegeneration

Mesh:

Substances:

Year:  2014        PMID: 24636248     DOI: 10.1016/j.eplepsyres.2014.02.001

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  10 in total

Review 1.  Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.

Authors:  Patricia B de la Tremblaye; Darik A O'Neil; Megan J LaPorte; Jeffrey P Cheng; Joshua A Beitchman; Theresa Currier Thomas; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2017-05-30       Impact factor: 8.989

2.  Animal Models of Posttraumatic Seizures and Epilepsy.

Authors:  Alexander V Glushakov; Olena Y Glushakova; Sylvain Doré; Paul R Carney; Ronald L Hayes
Journal:  Methods Mol Biol       Date:  2016

3.  Effects of lacosamide "a novel antiepileptic drug" in the early stages of chicken embryo development.

Authors:  Mesut Mete; Beyhan Gurcu; Fatih Collu; Ulkun Unlu Unsal; Yusuf Kurtulus Duransoy; Mehmet Ibrahim Tuglu; Mehmet Selcuki
Journal:  Childs Nerv Syst       Date:  2016-07-29       Impact factor: 1.475

4.  Increases of Catalase and Glutathione Peroxidase Expressions by Lacosamide Pretreatment Contributes to Neuroprotection Against Experimentally Induced Transient Cerebral Ischemia.

Authors:  Hyun Young Choi; Joon Ha Park; Bai Hui Chen; Bich Na Shin; Yun Lyul Lee; In Hye Kim; Jeong-Hwi Cho; Tae-Kyeong Lee; Jae-Chul Lee; Moo-Ho Won; Ji Hyeon Ahn; Hyun-Jin Tae; Bing Chun Yan; In Koo Hwang; Jun Hwi Cho; Young-Myeong Kim; Sung Koo Kim
Journal:  Neurochem Res       Date:  2016-05-21       Impact factor: 3.996

Review 5.  Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide.

Authors:  Sarah M Wilson; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2014-06-20       Impact factor: 5.590

6.  Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury.

Authors:  Sarah M Wilson; Seul Ki Yeon; Xiao-Fang Yang; Ki Duk Park; Rajesh Khanna
Journal:  Front Cell Neurosci       Date:  2014-05-28       Impact factor: 5.505

Review 7.  Modeling trauma in rats: similarities to humans and potential pitfalls to consider.

Authors:  Birte Weber; Ina Lackner; Melanie Haffner-Luntzer; Annette Palmer; Jochen Pressmar; Karin Scharffetter-Kochanek; Bernd Knöll; Hubert Schrezenemeier; Borna Relja; Miriam Kalbitz
Journal:  J Transl Med       Date:  2019-09-05       Impact factor: 5.531

Review 8.  Role of Astrocytes in Post-traumatic Epilepsy.

Authors:  Songbai Xu; Qihan Sun; Jie Fan; Yuanyuan Jiang; Wei Yang; Yifeng Cui; Zhenxiang Yu; Huiyi Jiang; Bingjin Li
Journal:  Front Neurol       Date:  2019-11-13       Impact factor: 4.003

9.  Neuroprotective Effects of Lacosamide in Experimental Peripheral Nerve Injury in Rats : A Prospective Randomized and Placebo-Controlled Trial.

Authors:  Serdar Demiroz; Koray Ur; Aydin Sukru Bengu; Aykut Ulucan; Yunus Atici; Sinan Erdogan; Alper Cirakli; Sevki Erdem
Journal:  J Korean Neurosurg Soc       Date:  2019-12-09

10.  Reduction of cytotoxicity of benzalkonium chloride and octenidine by Brilliant Blue G.

Authors:  Melinda Bartok; Rashmi Tandon; Gabriela Alfaro-Espinoza; Matthias S Ullrich; Detlef Gabel
Journal:  EXCLI J       Date:  2015-01-21       Impact factor: 4.068

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.